Browse Articles

Discover research articles across all indexed journals

Predictive value and mediating effect analysis of the AHR-ARNT-CYP1A1 axis for missed abortion related to polycyclic aromatic hydrocarbons exposure

Scientific Reports Jiuru Cao, Mei Han, Fuxing Li et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88464-9

ACCEL: [Ac-225]-PSMA-62 phase Ia/Ib/II clinical trial to characterize efficacy, safety, tolerability, and dosimetry in oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology Ramy Saleh, Kim N. Chi, Di Maria Jiang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps282

TPS282 Background: Actinium-225 (Ac-225)-based, prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) represents a promising treatment modality for prostate cancer. First-generation PSMA-targeting ligands (e.g., PSMA-617 and PSMA-I&T) paired with Ac-225 have been associated with myelosuppression, renal toxicity, and xerostomia (1). LY4181530 (previously PNT2001) pairs Ac-225 with PSMA-62, a next-generation ligand, which was specifically designed to overcome these limitations. It employs an improved linker technology that increases cellular internalization, leading to improved biodistribution, tumor delivery of Ac-225, and efficacy in preclinical models (2). Methods: ACCEL (NCT06229366) is a multi-center, open-label, multiple-arm, Phase Ia/Ib/II study evaluating the safety, tolerability, and efficacy of [Ac-225]-PSMA-62 in patients with oligometastatic hormone-sensitive prostate cancer (OmHSPC) and metastatic castration-resistant prostate cancer (mCRPC). Eligible patients with OmHSPC have metachronous disease, up to 5 PSMA-positive lesions, and have not initiated life-long ADT. Eligible patients with mCRPC have PSMA-positive lesions and have received prior androgen receptor pathway inhibitor, taxane chemotherapy (unless ineligible or declined), and up to 3 prior systemic therapy regimens in the mCRPC setting. Prior PSMA-targeted RLT, baseline Grade ≥1 xerostomia, and Grade ≥1 xerophthalmia are not permitted. In the Phase 1a, dose escalation decisions follow the Bayesian optimal interval (BOIN) design to separately determine the maximum tolerated dose of [Ac-225]-PSMA-62 for each patient population. In the Phase 1b, patients will be randomized to 2 or more arms to optimize dosing/schedule and inform the selection of the recommended Phase II dose of [Ac-225]-PSMA-62 for each patient population. The phase II aims to evaluate the efficacy of [Ac-225]-PSMA-62 compared to best standard of care in patients with mCRPC, with the primary endpoint being radiographic progression-free survival. The study is currently enrolling in Canada with plans to open in other countries. 1. Sathekge MM. et al. Lancet Oncol . 2024 Feb;25(2):175-183. 2. Vito A. et al. EP-039. Presented at EANM Oct 2022, Barcelona, Spain. Clinical trial information: NCT06229366 .

Bayesian re-analysis: Comparing radical cystectomy with trimodality therapy in patients with muscle invasive bladder cancer.

Journal of Clinical Oncology Abigail Pepin, Ronac Mamtani, John Paul Christodouleas et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.737

737 Background: Randomized trials comparing radical cystectomy (RC) and trimodality therapy (TMT) in muscle invasive bladder cancer (MIBC) have not been feasible. In 2023, Zlotta et al. published a retrospective multi-institutional analysis evaluating metastasis free survival (MFS) and overall survival (OS) outcomes in patients treated with RC or TMT. Zlotta et al. is generally considered the highest quality data available for this comparison, but the results were presented using traditional frequentist statistics which can be challenging to interpret. The purpose of this study was to use Bayesian re-analysis of Zlotta et al. to convert its frequentist summary statistics into outcome probabilities, enabling a more intuitive treatment comparison between RC and TMT. Methods: The Zlotta et al. study results comparing RC and TMT were described by estimating the probability of any benefit (HR<1) or a minimal clinically meaningful (MCR) benefit (HR<0.8). An informative neutral prior distribution was defined by surveying bladder cancer experts on the comparison of RC and TMT use in bladder cancer patients included in Zlotta et al. (cT2–T4N0M0, <7cm, no or unilateral hydronephrosis, no CIS, average age 70). Using a neutral prior of no advantage to either treatment and methods adapted from Wijeysundera et al., we calculated probabilities of a benefit in MFS and OS. We performed sensitivity analyses by varying the strength of the study-specific priors’ neutrality assumption and by using an alternative informative neutral prior developed for oncology comparisons but not specifically for MIBC. Results: The expert-informed informative neutral prior assumption assumed a 70% chance that any differences with respect to any cancer control or overall survival outcome would be less than the minimal clinically significant thresholds. The posterior probabilities of the primary analysis are presented in the table. Sensitivity analyses of the estimates of any benefit for MFS and OS varied by up to 3%, while estimates of a MCR benefit for MFS and OS varied up to 15%. Conclusions: The best available evidence suggests that in selected MIBC patients there is a >96% chance that TMT is associated with any OS advantage over RC but a <59% chance that the benefit reaches a minimal clinically meaningful benefit threshold. There is >65% chance that TMT is associated with any MFS advantage over RC but <13% chance of a minimal clinically meaningful benefit. Bayesian re-analysis of outcome estimate from Zlotta et al. 2023. Probability of any benefit of TMT over RC (HR<1) Probability of any benefit of RC over TMT (HR>1) Probability of a MCR benefit of TMT over RC (HR<0.8) Adjusted MFS Zlotta et al. Outcomes IPTS SHR 0.89 (95% CI 0·67–1·20) 73% 27% 12% PSM SHR 0.93 (95% CI 0.71–1.24) 66% 34% 7% Adjusted OS IPTS SHR 0.70(95% CI 0.53–0.92) 98% 2% 58% PSM SHR 0.75 (95% CI 0.58–0.97) 97% 3% 44%

Genomic characteristics of patients with metastatic hormone-sensitive prostate cancer treated with ARPI-based therapy: A single-center analysis.

Journal of Clinical Oncology Brigida Anna Maiorano, Antonio Cigliola, Chiara Mercinelli et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.244

244 Background: The addition of androgen receptor pathway inhibitors (ARPI) to androgen deprivation therapy (ADT) has improved survival in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC), both as doublets and as triplets with docetaxel. The prognostic role of genomic alterations (GA) is of growing interest in this setting. We evaluated the GA profiling of a population treated with ARPI-based therapy in a single-center institution. Methods: Our retrospective analysis included patients with mHSPC treated at IRCCS San Raffaele Hospital between 2020 (when ARPI were authorized for mHSPC in Italy) and 2023 (when triplets of ARPI + ADT + docetaxel were authorized). Included patients had a diagnosis of mHSPC, tissue biopsy available for genomic profiling, and were treated with ARPI plus ADT (plus or minus docetaxel) within 120 days of initial diagnosis. Comprehensive genomic profiling (CGP) using a commercial hybrid capture-based system (Foundation Medicine) was performed on all pts to evaluate all classes of GA, homologous recombination score (HRDsig), genomic ancestry, and signature. The log-rank test and Cox proportional hazards models compared GA between responders (Rs: defined as non-progressive pts) and not-responders (NRs: pts developing a progressive disease). Kaplan Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Results: 28 patients were included in our analysis. Among them, 25 pts received ARPI + ADT, 3 ARPI + ADT + docetaxel. The median age was 71.8 years (range 53.1-83.9). After a median follow-up of 55.1 months, there were no differences in median PFS (mPFS) between patients treated with triplets and doublets (55.42 vs. 78.0 mos - HR = 1.12; 95%CI, 0.13-9.87; p = 0.92). The median OS (mOS) was not reached in both subgroups, without significant differences in survival rates (HR = 0.32; 95%CI, 0.01-7.33; p = 0.48). The overall response rate was 71.4%, and the disease-control rate was 85.7%. Comparing the CGP profiling between responders and progressive-pts, SPOP mutations were more frequent among Rs than NRs to ARPI (25% vs 0%; p = 0.183). TMPRSS2 - ERG fusions, which tend to be less frequent in SPOP mutated cases, were less frequent in Rs (12.5%) than NRs (20.0% - p = 0.648). There was a similar incidence of other GAs between the two groups of pts, such as PTEN , BRCA1/2 , ATM , and CDK12 (all 12.5% vs. 10.0%; all p > 0.05). Conclusions: In a real-world setting, response to ARPI-based therapy may be associated with characteristic genomic features, such as SPOP mutations, or TMPRSS2 / ERG fusions, both in doublets and in triplet regimens. These findings underscore the importance of larger cohorts to further validate this hypothesis and inspire future research in the treatment selection for mHSPC pts.

Preferred treatment regimens for rare genitourinary (GU) malignancies.

Journal of Clinical Oncology Nicholas I. Simon, Stephanie A. Berg, Alan Tan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.780

780 Background: Rare GU cancers offer a challenge in determining standard of care therapy. Often data is extrapolated from small patient series or other tumor types to help guide clinicians. There is a lack of prospective data to guide therapy. Methods: We conducted a five-question survey via the Alliance for Clinical Trials in Oncology cooperative group network to identify commonly used and preferred regimens for the treatment of metastatic rare GU malignancies, including bladder squamous cell carcinoma (SCC), bladder adenocarcinoma, small cell bladder carcinoma (SCBC), penile SCC, and sex cord stromal tumors. Each question included 1) number of patients the provider treated per year, and 2) preferred frontline metastatic regimen for the rare tumor (multiple choice options drawn from the literature and selected after a discussion with a panel of experts (Table)). Surveys were emailed to the GU malignancy Alliance members, including academic and NCI Community Oncology Research Program (NCORP) sites. Responses were pooled and analyzed. Results: Fifty-one survey responses were received. One outlier was removed from the analysis leaving 50 responses. Twenty-six sites (52%) were NCORP, 22 sites were academic (44%), 2 sites were other. For the bladder SCC patients, the average number seen per year was 3.6 (range 0-15), 36.7% chose gemcitabine/platinum, 32.7% chose carboplatin/paclitaxel/gemcitabine, and 16.3% chose ITP as their preferred frontline regimen. For the adenocarcinoma bladder patients, the average number seen per year was 2.7 (range 0-10), 47.9% chose FOLFOX/CAPOX, 20.8% chose Gem-FLP, 16.7% chose FOLFOX/CAPOX + Bevacizumab and 6.2% chose ITP. For the SCBC patients, the average number seen per year was 3.1 (range 0-10), 62% chose platinum/etoposide with an immune checkpoint inhibitor compared to 36% who chose platinum/etoposide alone. For the penile SCC patients, the average number seen per year was 2.5 (range 0-10), 71.4% chose TIP,16.3% chose cisplatin/5FU and 10.2% chose immune checkpoint inhibitor. For the sex cord stromal tumor patients, the average number seen per year was 0.9 (range 0-10), 66.0% reported never treated and 19.2% chose BEP. Conclusions: This survey provides information on the most used regimens to treat rare GU malignancies and highlights the need for prospective studies to determine the best frontline therapy. These results are being used to inform the design of a first-line clinical trial to evaluate the most efficacious therapy for these rare GU malignancies. Survey Choices Option 1 Option 2 Option 3 Option 4 Option 5 - write in Bladder SCC ITP CarboTaxolGem GemPlatinum ddMVAC Bladder Adenocarcinoma ITP FOLFOX FOLFOX+bev Gem-FLP SCBC EP EP + ICI IA-EP Penile SCC TIP Cis/5FU ICI Cetuximab Sex Cord Stromal Tumor BEP VIP Never treated ITP - ifosfamide, paclitaxel, and cisplatin; EP – etoposide/platinum; IA-EP – ifosfamide/Adriamycin-EP; Gem-FLP – gemcitabine, 5-FU, leucovorin, cisplatin.

Exploring the science and data foundation for Federal public lands decisions

PLoS ONE Alison C. Foster, Andrew T. Canchola, Travis S. Haby et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0316013

Public lands provide diverse resources, values, and services worldwide. Laws and policies typically require consideration of science in public lands decisions, and resource managers are committed to science-informed decision-making. However, it can be challenging for managers to use, and document the use of, science and data in their decisions. To better understand science and data use in Federal public lands decisions in the United States, we assessed the number, type, and age of documents cited in 70 Environmental Assessments (EAs) completed by the Bureau of Land Management (BLM) in Colorado from 2015–2019. We focused on the BLM, as they manage the largest area of public lands in the United States. We selected Colorado as our study area, as actions proposed on BLM lands in Colorado are representative of those across the nation. Fifty percent of citations were categorized as science and 23% as data. EAs contained an average of 17 citations (range 0–111), with documents analyzing effects of oil and gas development and recreation actions including the highest and lowest mean number of citations (41 and 6, respectively). Of individual resource analysis sections within EAs, 24% contained ≥1 science citation and 21% contained ≥1 data citation. Journal articles were the most cited type of document (26% of citations) followed by non-BLM inventories (13%). Forty-seven percent of citations were relatively recent (2010 or later); the oldest citation was from 1927. Commonly analyzed resources with the highest mean number of citations were socioeconomics, mineral resources, and noise. Fourteen of 33 commonly analyzed resources included <1 citation on average. Actions and resources with no or few citations represent opportunities for strengthening the transparent use of science and data in public lands decision-making.

Anti-colorectal cancer activity of constructed oleogels based on encapsulated bioactive canola extract in lecithin for edible semisolid applications

Scientific Reports Engy M. Akl, Ahmed A. Abd-Rabou, Ayat F. Hashim Feb 10, 2025 DOI: 10.1038/s41598-025-88488-1

Abstract Globally, colorectal cancer ranks second in women and third in men. Hydrophilic anticancer agents have limited use in lipid systems due to their weak solubility. Therefore, this study aimed to develop oleogels based on pumpkin seed oil (R1) and hydrophilic bioactive canola extract (BCE or R2) that were extracted from canola meal by-products. BCE was effectively dispersed in oleogels through the encapsulation of BCE with various concentrations (0.08, 0.2, and 0.4%) in soy lecithin to form BCE gelling agents. Four formulations (F1 as plain, F2-F4 with different concentrations of BCE) were produced using two gelators (BCE gelling agent and beeswax). The oxidative stability, microstructure, FTIR, antioxidant activity, and time-dependent experiment were investigated. The cytotoxicity against colorectal HCT116 and Caco-2 cancer cell lines in vitro was evaluated. The anti-apoptotic PI3k and COX-2 protein expressions were also assessed. The peroxide, p-anisidine, and total oxidation values of F4 were 7.85, 26.66, and 42.35, respectively, during 60 days at 60 ± 2 °C. The antioxidant activity values of F4 were 74.40% for DPPH, 54.28% for ABTS, and 5.77 mg/g for FRAP. F4 demonstrated the highest significant cytotoxic effects on cancerous cells, particularly in the Caco-2 cells with 1.40- and 1.41-fold increases compared to R2 and the positive control doxorubicin, respectively. PI3k and COX-2 expression levels were down-regulated while iNOS activity was up-regulated in both cells, with very high down-regulation recorded for F4 in Caco-2 cells. This study developed a method for producing stable lipid products loaded with hydrophilic antioxidants that may be used as an anti-colorectal platform.

Real-world analysis of 2IR immune response score in urothelial carcinoma (UC).

Journal of Clinical Oncology Jason Robert Brown, Tolulope Tosin Adeyelu, Andrew Elliott et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.739

739 Background: Immune checkpoint inhibition (ICI) is often used to treat UC, however many patients (pts) exhibit resistance. Using bulk RNA sequencing of pre-treatment tissue from ImVigor 210 and CheckMate 275 trials, an immune response score (2IR) was previously developed to predict ICI response by determining the comparative expression of genes involved in anti-tumorigenic adaptive immune response and pro-tumorigenic inflammation. Here, we evaluated the 2IR score as a prognostic or predictive biomarker in real-world pts with UC. Methods: Specimens from pts with UC (n = 6395) were profiled at Caris Life Sciences (Phoenix, AZ) using next generation sequencing (NGS) of DNA and RNA. 2IR was calculated by comparative RNA expression of 10 adaptive immune genes and 39 pro-tumorigenic genes. Tumors were classified as 2IR-Low (2IR ≤ -0.5), -Mid (-0.5 < 2IR < 0), and -High (2IR ≥ 0) as previously described. Spearman correlation analysis was utilized to compare 2IR with PD-L1 combined proportion score (CPS), tumor mutation burden (TMB), interferon score (IFN) and the tumor microenvironment (TME) cell fractions estimated using quanTIseq. Clinical outcomes included real-world overall survival (OS) from ICI start to last contact and time on treatment (ToT) with pembrolizumab, obtained via matched insurance claims data and calculated using Kaplan-Meier methods while Hazard ratio (HR) was calculated by Cox proportional model. Results: Of the 6395 UC samples, 9.5% (n = 611) were classified as 2IR-High, 42.7% (n=2730) 2IR-Mid, and 47.8% (n=3054) 2IR-Low. In pts with Upper Tract UC primary (UTUC, n = 1104), 2IR was comparatively lower than in pts with bladder cancer primary (BC, n = 4923) (median: -0.53 vs. -0.47, p < 0.001). 2IR shows a positive correlation with TMB (r = 0.23; p < 0.001), IFN score (r = 0.21; p < 0.001) and insignificant correlation with PD-L1 CPS (r = 0.09; p <0.001). 2IR-High positively correlated with mutations in TP53 , RB1 , and ARID1A (all p < 0.0001), amplification of ERBB2 (p < 0.0001), and microsatellite-instability high status (p < 0.0001), but not with FGFR3 mutations or fusions. 2IR positively correlated with immune cell fractions, such as CD4 + T (r = 0.09), CD8 + T (r = 0.22), and dendritic cell (r = 0.18), but negatively correlated with B cells (r = -0.06), M1 macrophages (r = -0.25), M2 macrophages (r = -0.08) and neutrophils (r = -0.12). Pts treated with 2IR-High tumors had longer ToT on pembrolizumab (HR = 0.65 CI 0.55 - 0.77, p <0.001) and OS from ICI start (HR = 0.51, CI 0.41 – 0.62, p < 0.001) compared to pts with 2IR-Low UC. This association held for both primary BC and UTUC. Conclusions: In a real-world cohort, we validate the 2IR score and suggest that it is prognostic for OS and predictive for pembrolizumab ToT, consistent with a positive correlation with known predictors of ICI response. Prospective studies are needed to further validate this biomarker for use in clinical practice, especially given the evolving UC treatment landscape.

Clinical use and outcomes of androgen-receptor pathway inhibitors triplet therapy for metastatic hormone-sensitive prostate cancer (ARAAT).

Journal of Clinical Oncology Rana R. McKay, Alicia K. Morgans, Nasreen Khan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.66

66 Background: In the pivotal phase 3 ARASENS trial, patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide in combination with androgen-deprivation therapy (ADT) + docetaxel (DOC) had longer overall survival (OS) vs ADT+DOC. Triplet therapy with darolutamide or abiraterone is recommended for high-risk patients with mHSPC; however, data on routine clinical use and outcomes of triplet therapy are lacking. Methods: This retrospective cohort analysis used the ConcertAI Patient360 database, a geographically diverse US oncology electronic medical record source. Adult patients with mHSPC who initiated triplet therapy with darolutamide+ADT+DOC (DAR) or abiraterone+ADT+DOC (ABI) from 1/2020–1/2024 were included. Outcomes included the proportion of patients achieving prostate-specific antigen (PSA) response (≥90% decline or undetectable levels <0.2 ng/mL), treatment discontinuation, progression to metastatic castration-resistant prostate cancer (mCRPC), and OS. PSA response during index treatment is reported at 6 and 12 months. Kaplan–Meier (K–M) estimated probability for discontinuation and progression to mCRPC are reported at 18 months. Results: A total of 243 patients initiated DAR (n=141) and ABI (n=102) for mHSPC. The median age was 66 years; 80% had an Eastern Cooperative Oncology Group performance status score of 0/1; and >80% completed ≥6 DOC cycles. The median baseline PSA was 36 ng/mL for DAR vs 20 ng/mL for ABI. Median follow-up duration was 16 months for the DAR cohort and 19 months for the ABI cohort. More patients in the DAR cohort achieved a PSA response at 6 and 12 months compared with those in the ABI cohort (Table). At 18 months, K–M probability of discontinuation was 25% for DAR vs 38% for ABI, and probability of progression to mCRPC was 24% for DAR vs 46% for ABI (Table). At the end of the follow-up period, 91% of patients in the DAR cohort were alive compared with 78% in the ABI cohort. Conclusions: Using a real-world dataset, treatment discontinuation rates, progression to mCRPC, and PSA responses were all favorable in patients with mHSPC receiving triplet therapy with DAR vs ABI. Further investigation is warranted. Key study outcomes. Key outcomes DAR (n=141) ABI (n=102) PSA drop ≥90% from baseline At 6 months* 90 (88.2%) 38 (65.5%) At 12 months † 94 (91.3%) 43 (74.1%) PSA drop to undetectable level (<0.2 ng/mL) At 6 months* 45 (44.1%) 19 (32.8%) At 12 months † 63 (61.2%) 27 (46.6%) K–M probability of treatment discontinuation at 18 months (95% CI) 0.245 (0.177−0.334) 0.376 (0.286−0.484) K–M probability of progression to mCRPC at 18 months (95% CI) 0.244 (0.175−0.335) 0.460 (0.358−0.574) For the PSA response analysis, patients were required to have baseline PSA ≥1 ng/mL and >1 ng/mL PSA test during index treatment. *At 6 months, DAR n=102; ABI n=58. † At 12 months, DAR n=103; ABI n=58. CI, confidence interval.

Patterns of next-generation sequencing and associated next-line systemic therapy use in metastatic prostate cancer.

Journal of Clinical Oncology Julia Shi, Changchuan Jiang, Hamid Ghaderi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.105

105 Background: Next-generation sequencing (NGS) testing is used for prognostication and to guide treatment choice in metastatic prostate cancer (mPC). While NGS testing is increasingly available, how its usage has impacted real-world selection of next line therapies including olaparib in mPC is unclear. Methods: We performed a retrospective observational study using the real-world nationwide U.S. Flatiron Health electronic health record-derived de-identified mPC database with patients diagnosed between January 1 st , 2013, and July 30 th , 2024. Due to limitations of follow-up, patients diagnosed with mPC in 2024 were excluded. Rates of patients with documented NGS testing within 6 months of metastatic prostate cancer diagnosis, short-interval changes in systemic therapy defined as initiation of a new therapy within 30 days after NGS testing, and olaparib initiation within 60 days of NGS testing were analysed. Results: A total of 24,222 mPC patients were included, of which 6282 (25.94%)had at least 1 documented NGS test and 1494 (23.78%) of those patients had more than 1 NGS test. NGS test documentation after metastatic diagnosis increased from 0.175% in 2013 to 22.8% in 2023. The median time from metastatic diagnosis to initial NGS testing was 413 days (IQR 76-993). The percentage of NGS tests associated with short-interval initiation of a new line of therapy increased from 14.29% of patients receiving NGS testing in 2014 to 24.19% of patients receiving NGS testing in 2023. The most common therapies initiated within 30 days after NGS testing were abiraterone (37.75%), enzalutamide (13.91%), and docetaxel (10.93%). Among patients with documented NGS testing, the percent who initiated olaparib within 60 days of an NGS test increased from 0.31% in 2015 to 17.34% in 2024, with the greatest year-on-year increase in 2020 corresponding to FDA approval for patients with homologous recombination repair gene alterations. Median time to olaparib initiation after metastatic diagnosis was 798 days (IQR 455-1383). Conclusions: There was a significant increase in rates of documented NGS test for patients diagnosed with mPC over the past decade. Furthermore, systemic therapy change appears to be more frequently influenced by NGS testing, with a significant increase in associated olaparib initiation as next-line therapy.

Evaluation of a variant origin prediction (VOP) algorithm to distinguish clonal hematopoiesis (CH) variants from tumor-derived variants and to predict metastatic castrate resistant prostate cancer (mCRPC) clinical responses.

Journal of Clinical Oncology Daokun Sun, Shai He, Derek W Brown et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.201

201 Background: VOPis an algorithm that predicts the cellular origin of variants, currently available on FoundationOneLiquid CDx (F1LCDx) for research use only. IMbassador250 (IM250, NCT03016312) is a completed phase III trial that evaluated the safety and efficacy of atezolizumab in combination with enzalutamide for men with mCRPC who had prior progression on abiraterone. Here, we evaluated the prediction accuracy and demonstrated clinical validity of VOP with IM250 samples. We hypothesized that excluding predicted CH variants from maximum variant allele frequency (maxVAF) calculations would strengthen the association of reduction of maxVAF and clinical outcome and lead to better on treatment risk stratification. Methods: We developed VOP, a machine learning algorithm that classifies short variants into tumor somatic, CH, and germline categories based on fragmentomics and other features. We applied VOP to banked IM250 plasma samples from cycle 1 day 1 (C1D1) and cycle 3 day 1 (C3D1, 6 weeks on treatment) timepoints profiled by F1LCDx, and sequenced matched whole blood (WB) from a subgroup of patients to definevariant origin ground truth for an accuracy assessment. To assess clinical validity of VOP, we calculated maxVAF with and without filtering out CH variants predicted by VOP and assessed its association with clinical outcome. Results: Based on over 2,700 short variants in 221 patients with matched WB as truth, VOP achieved a positive percent agreement (PPA) of 92% and positive predicted value (PPV) of 94% for tumor somatic variant predictions (median VAF 3.6%). PPA and PPV were 90% and 88%, respectively, for CH variant predictions (median VAF 0.7%), and over 98% for germline variant predictions, consistent with past development data based on a pan-cancer cohort. To assess potential clinical impact, we applied VOP to 422 patients with F1LCDx results at both C1D1 and C3D1. Patients with at least 50% decrease in maxVAF were associated with longer overall survival. Importantly, CH-adjusted maxVAF led to better patient stratification (Hazard Ratio (HR) = 0.36 [0.28, 0.47], p = 0.0007) than non-CH-adjusted maxVAF (HR = 0.60 [0.45, 0.81], p < 0.0001). We observed similar results using cutoffs of 90% and 100% (ctDNA clearance) decrease in maxVAF and with radiographic progression-free survival as the endpoint. Conclusions: VOP had strong analytical concordance and clinical applicability in an independent mCRPC cohort (IM250). With the aid of VOP, CH-adjusted maxVAF more effectively identifies patients with better outcomes. The VOP algorithm is accurate, robust, and has potential clinical use in tumor monitoring, clinical outcomes and on treatment patient risk stratification.

Family correlates of behavioral problems among adolescents in Rwanda

PLoS ONE Eugene Harerimana, Jean d’Amour Muziki, Eric Nshimyumuremyi et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0314507

Background Globally, 20% of adolescents exhibit behavioral problems. Behavioral problems are associated with individual and environmental factors. However, little is known about the contribution of the nuclear family to the development of behavioral problems in adolescents from sub-Saharan Africa. This study aimed to explore family-based correlates influencing behavioral problems among adolescents in Rwanda. Methods With an institutional-based cross-sectional study design, a convenience sample of 158 participants {107 males and 51 females; Mean age (M) = 16.96, Standard Deviation (SD) = 1.86; age ranging from 13 to 23 years} was selected in secondary schools in the Nyarugenge district. Participants filled out Behavioral Problems Scale (BPS), Child and Adolescent Trauma Screen (CATS), University of California, Los Angeles Loneliness Scale (UCLA Loneliness Scale), Multidimensionality of Perceived Social Support Scale (MSPSS), Multidimensional Neglectful Behavior Scale (MNBS), and Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) to record pertinent scores. Socio-demographic information was also collected. SPSS version 24 was used for statistical analysis. Results Females exhibited more behavioral problems than males. Child and adolescent trauma (β = 0.705, t = 8.21, p < .001) and neglect (β = 0.147 t = 2.15, p < .05) were two significant family correlates in our sample. Poor quality of life enjoyment and satisfaction, loneliness, and poor parental perceived social support were not identified as family-based factors that influence behavioral problems in our sample. Conclusions Results highlighted the importance of implementing family and community-based interventions to sustain family well-being, change parenting behaviors, and help children and adolescents adopt positive behaviors.

BO-CLAHE enhancing neonatal chest X-ray image quality for improved lesion classification

Scientific Reports Jiwon Han, Byungmin Choi, Jae Young Kim et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88451-0

Abstract In the case of neonates, especially low birth weight preterm and high-risk infants, portable X-rays are frequently used. However, the image quality of portable X-rays is significantly lower compared to standard adult or pediatric X-rays, leading to considerable challenges in identifying abnormalities. Although attempts have been made to introduce deep learning to address these image quality issues, the poor quality of the images themselves hinders the training of deep learning models, further emphasizing the need for image enhancement. Additionally, since neonates have a high cell division rate and are highly sensitive to radiation, increasing radiation exposure to improve image quality is not a viable solution. Therefore, it is crucial to enhance image quality through preprocessing before training deep learning models. While various image enhancement methods have been proposed, Contrast Limited Adaptive Histogram Equalization (CLAHE) has been recognized as an effective technique for contrast-based image improvement. However, despite extensive research, the process of setting CLAHE’s hyperparameters still relies on a brute force, manual approach, making it inefficient. To address this issue, we propose a method called Bayesian Optimization CLAHE(BO-CLAHE), which leverages Bayesian optimization to automatically select the optimal hyperparameters for X-ray images used in diagnosing lung diseases in preterm and high-risk neonates. The images enhanced by BO-CLAHE demonstrated superior performance across several classification models, with particularly notable improvements in diagnosing Transient Tachypnea of the Newborn (TTN). This approach not only reduces radiation exposure but also contributes to the development of AI-based diagnostic tools, playing a crucial role in the early diagnosis and treatment of preterm and high-risk neonates.

Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.

Journal of Clinical Oncology Laurence Albiges, Robert J. Motzer, Sergio Trevino et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.438

438 Background: In the randomized, double-blind, phase 3 COSMIC-313 study (NCT03937219), C+N+I significantly improved PFS compared with N+I in first-line intermediate or poor risk aRCC, meeting the primary endpoint (Choueiri et al. N Engl J Med 2023). Here, we present the secondary endpoint of OS, updated efficacy and safety results, and biomarker analyses. Methods: Patients (pts) with previously untreated, IMDC intermediate or poor risk aRCC were randomized to receive C 40 mg QD or placebo (P). Both groups received N (3 mg/kg IV Q3W) + I (1 mg/kg IV Q3W) for 4 cycles, followed by N (480 mg IV Q4W) for up to 2 y. The primary endpoint was PFS by blinded independent central review per RECIST 1.1 in the first 550 randomized pts (previously reported). The secondary endpoint was OS in all randomized pts. A random forest model was used to identify immune subsets (deconvoluted from RNA-Seq data) associated with improved OS with C+N+I vs P+N+I. Results: A total of 855 pts were randomized to C+N+I (n=428) or P+N+I (n=427); IMDC risk was intermediate for 75% and poor for 25%. At a median follow-up of 45.0 months, an improvement in PFS with C+N+I was maintained (Table). OS was not significantly different between C+N+I and P+N+I in the ITT population or by IMDC risk group. ORR was higher with C+N+I, with a lower incidence of PD as best response. Grade 3/4 treatment-emergent AEs (TEAEs) occurred in 81% (C+N+I) vs 62% (P+N+I); most common grade 3/4 TEAEs were increased ALT (27% vs 6%) and increased AST (20% vs 5%). Grade 5 treatment-related AEs (TRAEs) occurred in 1% of pts in each group. No significant differences in OS outcomes were observed based on baseline c-Met or PD-L1 levels. Exploratory biomarker analyses showed that higher M2 macrophage abundance was associated with improved OS with C+N+I (HR, 0.51; 95% CI, 0.31–0.86), poor risk (per IMDC), high baseline sum of target lesions, and the presence of visceral metastasis. Biomarker analysis of angiogenic and immune signatures is ongoing. Conclusions: First-line treatment with C+N+I continued to demonstrate PFS and ORR benefit over P+N+I for pts with intermediate or poor risk aRCC. OS was comparable between the two arms, and no new safety signals emerged.Pts whose tumors have high M2 macrophage abundance had improved OS with C+N+I treatment. Clinical trial information: NCT03937219 . C+N+I (n=428) P+N+I (n=427) Median OS (95% CI), mo 41.9 (34.8–47.9) 42.0 (34.9–53.1) HR (95% CI); P- value 1.02 (0.85–1.23); P= 0.84 Median PFS (95% CI), mo 16.6 (14.0–22.6) 11.2 (9.3–14.0) HR (95% CI) 0.82 (0.69–0.98) ORR (95% CI), % 46 (41–51) 37 (32–41) Complete response, % 4 3 Partial response, % 42 33 Stable disease, % 40 36 Progressive disease, % 8 20

Tumor necrosis factor alpha signaling activity and NCCN risk, adverse pathology, and progression during active surveillance in prostate cancer.

Journal of Clinical Oncology Conor Driscoll, Nicole Handa, Yangyang Hao et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.415

415 Background: Elevated serum levels of tumor necrosis factor alpha (TNF-α) are characteristic of chronic inflammatory conditions and advanced prostate cancer (PCa). Local and systemic inflammation associated with TNF-α may enhance oncogenicity in the prostate. This study investigates the association between intra-tumoral TNF-α levels, NCCN risk, adverse pathology (AP) at radical prostatectomy (RP), and progression on active surveillance (AS). Methods: Intra-tumoral TNF-α pathway expression levels were assessed through TNF-α signaling via the NF-kB pathway. Transcriptomic profiles from 82,470 prospectively collected biopsy samples with the Decipher prostate genomic classifier (Veracyte, San Diego, CA) retrieved from the Decipher GRID registry (NCT02609269) were used to compare TNF-α levels by quartile across NCCN risk groups, Decipher score, and basal-luminal prostate subtype classifier (PSC). Transcriptomic data from a retrospective study of 647 patients with low or favorable intermediate risk (FIR) disease treated with RP were used in logistic regression to examine TNF-α levels with AP (any of Gleason grade group ≥3, SVI or LNI). A cohort of 28 favorable disease patients prospectively tested (2019-2024) with Decipher and managed with AS compared TNF-α levels with Wilcoxon for the binary endpoint of progression on AS. For progression, data from a retrospective study at a single academic center (2019-2024) were classified based on progression status (n=17 progressed, n=11 did not) following Decipher analysis of their initial biopsy specimens. Results: Among 82,470 PCa patients, the proportion of highest quartile TNF-α signature increased across NCCN low to very high risk prostate cancer and the lowest quartile decreased with increased NCCN risk group (Fisher’s exact test p < 2.2e-16). Median Decipher score was 0.57 (IQR 0.38-0.78) in the highest quartile TNF-α compared to 0.38 (IQR 0.24-0.58) for the lowest. The majority of samples with the highest TNF-α were PSC basal (73%) whereas the lowest were PSC luminal (76%) subtypes. Among 647 FIR disease patients treated with RP, higher TNF-α levels were significantly associated with AP (univariable OR 3.41, p=0.02; multivariate OR 2.93, p=0.05). In the AS cohort, elevated TNF-α signature correlated with a higher likelihood of progression. Conclusions: Increased TNF-α signaling levels are associated with increasingNCCN and Decipher risk groups and basal subtype. Elevated TNF-α levels in patients with FIR disease tumors had higher risk of AP at RP. In AS, higher TNF-α signaling was associated with progression and it may serve as a tool to guide treatment counseling. Uni- and multivariable analysis for pT3b+, GG 3-5, or LNI+. Univariable OR (95% CI) P-value Multivariable OR (95% CI) P-value TNF-α 3.41 (1.21 – 9.12) 0.02* 2.93 (1.01 – 8.02) 0.05* CAPRA - - 1.43 (1.08 – 1.91) 0.01* *p < 0.05 denotes significance.

Influence of gut microbiome composition on treatment efficacy and toxicity in bladder cancer: A comprehensive meta-analysis.

Journal of Clinical Oncology Atif Hussain Sarwar, Hashim Talib Hashim, Ahmed Qasim Mohammed Alhatemi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.768

768 Background: The gut microbiome has emerged as a critical factor influencing the efficacy and toxicity of cancer treatments. In bladder cancer, variations in microbiome composition may affect patient responses to therapy, including immunotherapy and chemotherapy. This meta-analysis aims to comprehensively evaluate the impact of gut microbiome composition on treatment outcomes in bladder cancer. Methods: The PubMed, Embase, Scopus and Cochrane databases were systematically searched from inception until June 2024 using relevant keywords. The pooled data were presented as Odds Ratio (OR) with 95% confidence intervals (CI) using Random Effects model in OpenMeta (version 5.3). The I 2 and X 2 statistics were used to evaluate inter-study heterogeneity. An I 2 value of >50% was considered significant heterogeneity. The subgroup analyses were conducted to identify specific microbiome profiles associated with different treatment responses. Results: A total of 20 studies comprising 2,500 bladder cancer patients were included in the meta-analysis. Patients with a higher abundance of beneficial bacteria such as Bifidobacterium and Lactobacillus had significantly better treatment responses (OR: 2.5, 95% CI: 1.8-3.4) and lower toxicity rates (OR: 0.6, 95% CI: 0.4-0.9). Conversely, an increased presence of pathogenic bacteria like Clostridium and Escherichia coli was associated with poorer outcomes (OR: 0.5, 95% CI: 0.3-0.8) and higher toxicity (OR: 1.9, 95% CI: 1.3-2.7). Conclusions: This meta-analysis highlights the significant influence of gut microbiome composition on the efficacy and toxicity of bladder cancer treatments. Identifying specific bacterial profiles associated with positive and negative outcomes could guide personalized treatment strategies and improve patient care. Further research is needed to understand the mechanisms underlying these associations and to develop microbiome-targeted therapies.

Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.

Journal of Clinical Oncology Shuang Zhao, Hyunnam Monica Ryu, James A. Proudfoot et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.308

308 Background: NRG/RTOG 0126 and SAKK 09/10 were phase III randomized trials examining whether higher dose resulted in better response/outcomes in PCa patients following definitive and post-operative RT, respectively. RTOG 0126 showed a benefit for RT dose escalation (DE) from 70.2Gy to 79.2Gy though SAKK 09/10 did not show a benefit from 64Gy to 70Gy. We hypothesized that a previously developed 24-gene prostate cancer RT gene expression score (PORTOS) could distinguish patients who benefited from RT DE in both trials. Methods: PORTOS scores were calculated on biopsy samples in RTOG 0126 and prostatectomy samples in SAKK 09/10 as published. Since the original PORTOS cutoffs were in the post-op setting, we utilized tertile score groups in RTOG 0126, whereas the published PORTOS cutoffs were used for SAKK 09/10. The primary objective was to evaluate PORTOS as a predictive biomarker for the benefit of RT DE on biochemical failure (BF) via the Phoenix criteria in RTOG 0126 (N=215) and clinical progression-free survival (CFPS) in SAKK 09/10 (n=226). In addition, we also investigated clinical and molecular correlates of PORTOS in large real-world datasets of 31,107 prostate biopsy samples and 42,407 radical prostatectomy samples. Results: In RTOG 0126, in patients with lower tertile PORTOS scores, there was no difference in Phoenix BF (sHR 1.14 [0.54-2.40], P=0.73). However, for patients in the middle and higher tertile PORTOS score range, there was a significant benefit for RT DE for Phoenix BF (middle PORTOS: sHR 0.45 [0.22-0.90], P=0.02; higher PORTOS: sHR 0.30 [0.12-0.75], P=0.009). An interaction test indicated a significant difference in benefit for DE between higher and lower PORTOS groups (P=0.048). Similarly in the post-op SAKK 09/10 trial, only patients in the higher PORTOS score group benefited from RT DE (CPFS HR 0.19 [0.05-0.70]; P=0.01), with a significant biomarker-treatment interaction between lower vs. higher PORTOS and treatment arm (P=0.003). Interestingly, PORTOS was not consistently associated with clinicopathologic variables in either trial or in the large real-world biopsy or prostatectomy datasets. Biologically, in the real-world datasets, PORTOS was modestly associated with hypoxia signatures consistent with its role in radio-resistance, and strongly associated with immune signatures and molecular subtypes. Conclusions: In two phase III randomized trials, we have validated that PORTOS can identify patients who benefit as well as those that do not benefit from RT DE for localized PCa and provides the first randomized evidence for any biomarker to be able to predict RT dose response. PORTOS could be used to personalize radiation dose for patients with prostate cancer clinically, and allow selection of patients most likely to benefit from RT DE while sparing others from the potential increased risk of toxicity.

Digital assessment of walking ability: Validity and reliability of the automated figure-of-eight walk test in older adults

PLoS ONE Hyun-Ho Kong, Kwangsoo Shin, Dong-Seok Yang et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0316612

Background The Figure-of-Eight Walk Test (F8WT) can assess straight- and curved-path walking ability, but the validity and reliability of automated measurement of the F8WT using digital device has not yet been studied. The aim of this study was to verify the validity (method comparison) and test-retest reliability of the automated FW8T (aFW8T) using a digital device based on image analysis by comparing the results of the aF8WT with those of the manual F8WT (mF8WT). Methods Community-dwelling older adults underwent the mF8WT performed by a physiotherapist and the aF8WT using the Digital Senior Fitness Test system. To verify the test-retest reliability, the aF8WT was administered again to a randomly selected group of participants one week after the baseline test. The intraclass correlation coefficient (ICC) and Pearson’s correlation analysis were used to verify the degree of agreement between the results of and correlation between the mF8WT and aF8WT, respectively. The 95% confidence interval (CI) of the limits of agreement (LoA) was obtained using Bland–Altman analysis. Results The analysis included 83 participants (mean age 71.6 ± 4.7 years). The participants’ mF8WT and aF8WT results were 29.1 ± 4.9 and 29.8 ± 4.9 seconds, respectively. Pearson’s correlation analysis showed a very strong correlation between the mF8WT and aF8WT results with r = 0.91 (p < 0.001), and the ICC between the mF8WT and aF8WT results was 0.95 (0.91–0.97), showing excellent agreement. The 95% CI of the LoA was ˗0.7 (˗4.8 to 3.3) seconds in the Bland–Altman analysis. In an analysis of the test-retest reliability of the aF8WT, participants’ aF8WT results were 30.9 ± 4.7 seconds (baseline) and 29.6 ± 4.9 seconds (retest), with an ICC of 0.94 (0.81–0.98, p < 0.001), indicating excellent reliability. Conclusion Automated measurement of the F8WT using a digital device showed excellent validity and reliability. The aF8WT can be used to assess and monitor the walking ability of community-dwelling older adults.

Potassium KCa3.1 channel overexpression deteriorates functionality and availability of channels at the outer cellular membrane

Scientific Reports Natalia V. Bal, Ilya Oblasov, Victor N. Ierusalimsky et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89097-8

Postoperative adjuvant treatment of HER2 overexpression in upper urinary tract urothelial carcinoma with the combination of disitamab vedotin and toripalimab: A real-world retrospective study.

Journal of Clinical Oncology Shun Zhang, Shiwei Zhang, Yongming Deng et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.673

673 Background: Radical nephroureterectomy (RNU) bears a high recurrence risk. Thus, postoperative treatment is necessary for upper urinary tract urothelial carcinoma (UTUC) patients. The CheckMate-274 study proved the feasibility of immunotherapy after surgery for urothelial carcinoma (UC), but showing no significant efficacy difference compared to placebo in UTUC. Disitamab vedotin is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody disitamab and MMAE payload. Clinical studies have showed that combining Disitamab vedotin with Toripalimab is an efficacious regimen for advanced urothelial carcinoma. Thus, we are investigating whether this combination therapy following RNU can offer improved survival outcomes. Methods: A retrospective analysis was conducted on data from patients who underwent RNU at Nanjing Drum Tower Hospital between April 2022 and April 2024. The study included patients pathologically diagnosed with cT 2-4a N 0 M 0 UTUC and HER2 positive status (HER2 IHC2+ or HER2 IHC3+). Patients received 26 cycles of Toripalimab (240mg, IV, Day 1, q2w) combined with 8 cycles of Disitamab vedotin (2mg/kg, IV, Day 1,q2w). CT scans of the chest and abdomen were performed every three months. The primary endpoint was the 12-month disease-free survival (DFS) rate. Results: The study included 36 cases of UTUC patients after RNU. Among them, 12 cases received treatment with Disitamab vedotin combined with Toripalimab, while 24 cases did not receive postoperative adjuvant therapy. In the treatment group, the 12-month DFS rate was 91.7% (1/12), compared to 62.5% (9/24) in the non-adjuvant therapy group. The most common treatment-related adverse events (TRAEs) in the treatment group were abnormal liver function (41.6%), decreased appetite (50%), and peripheral sensory neuropathy (33.3%), with no Grade 3 or higher adverse events observed. Conclusions: Disitamab vedotin combined with Toripalimab demonstrated efficacy as adjuvant therapy following radical nephroureterectomy for UTUC. Based on the one-year DFS outcomes, this combination could be considered as an adjuvant therapy option post-surgery.